English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessCOVID-19 treatment | Gilead says Indian licensees free to price Remdesivir: Report

    COVID-19 treatment | Gilead says Indian licensees free to price Remdesivir: Report

    Gilead Sciences' experimental drug Remdesivir has been found to aid in the recovery of COVID-19 patients.

    Moneycontrol News
    June 04, 2020 / 10:18 IST
    Representative image

    Gilead Sciences has said its licensed manufacturers in India are free to fix the price of Remdesivir, The Economic Times has reported.

    Remdesivir is the experimental drug used for treating patients of COVID-19, the disease caused by the novel coronavirus.

    The report further cites the United States-based company as saying that its own brand of Remdesivir will be available in India from July.

    Gilead Sciences' experimental drug Remdesivir has been found to aid in the recovery of COVID-19 patients.

    In India, the US-based company has licensing agreements for Remdesivir with four pharmaceutical companies — Cipla, Hetero Drugs, Jubilant Life Sciences and Mylan.

    COVID-19 Vaccine

    Frequently Asked Questions

    View more
    How does a vaccine work?

    A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

    How many types of vaccines are there?

    There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

    What does it take to develop a vaccine of this kind?

    Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

    View more
    Show

    Related stories

    Also read | Gilead's Remdesivir could see $7 billion in annual sales on stockpiling boost: Analyst

    A Gilead spokesperson told the newspaper that generic manufacturers would be free to set prices. “It is our hope and intent that volumes and competition will drive costs down,” the spokesperson added.

    The report further cites a private physician in Mumbai as saying that distributors of Hetero Pharma, one of the licensees, are quoting Rs 7,000 per 100 mg vial for the generic version of Remdesivir.

    At this price, a five-day full course would cost Rs 35,000- Rs 42,000. Moneycontrol could not independently verify the report.

    Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

    However, it was earlier reported that Indian pharmaceutical companies are yet to receive an approval to market Remdesivir.

    It was also reported earlier that companies licensed to manufacture Remdesivir might have to sell it only to government institutions for now as the drug was still under trial.

    Gilead Sciences is reportedly developing easier-to-administer versions of Remdesivir for COVID-19 that could be used outside of hospitals, including ones that can be inhaled, after trials showed moderate effectiveness for the drug given by infusion.

    For critically-ill patients, Roche and Eli Lilly and Co are testing drugs in combination with Remdesivir.

    Click here for Moneycontrol’s full coverage of the novel coronavirus pandemic

    Moneycontrol News
    first published: Jun 4, 2020 10:18 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347